A Randomized, Double-Blind, Phase II Trial of Fulvestrant Plus Enzastaurin Versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Enzastaurin (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 02 Nov 2018 Status changed from active, no longer recruiting to completed.
- 14 Sep 2018 Planned End Date changed from 1 Dec 2018 to 30 Dec 2018.
- 25 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History